Sanofi raises its growth prospects and climbs on the stock market
For the second time, sales of Dupixent exceeded 5 billion euros in a single quarter.
To save an article you must be connected, so you can view them on all your devices.
For the second time, sales of Dupixent exceeded 5 billion euros in a single quarter.
The Sanofi locomotive is moving ever faster. The French pharmaceutical laboratory raised its growth outlook for 2026 for the second time on Friday, when it published its results for the third quarter.
Its turnover increased by 16.2% during this period, driven once again by Dupixent, its best-selling drug. It is a biological treatment indicated in the treatment of eczema, asthma and chronic obstructive pulmonary disease (COPD). Its sales increased by almost 25% in the third quarter. They have, for the second time, exceeded 5 billion euros in a single quarter. For the year as a whole, Sanofi is now targeting revenue growth of just over 10%. On the stock market, the value of Sanofi shares increased on Friday by almost 5%.
The whole challenge for the pharmaceutical laboratory and its new manager, Belén Garijo, now consists of anticipating the next…
This article is reserved for subscribers. You have 43% left to discover.
Machine-translated from French
Not cross-checked yet
Only Le Figaro reports this story so far. We show it as a single source until another newsroom confirms it.
- Le Figaro30 Oct, 19:32Sanofi raises its growth prospects and climbs on the stock market ↗Figures: 5 milliards
| Publisher Le Figaro (established tier) | +76 |
| Checkable figures cited | +3 |
| Total | 79 |
Method: reports are grouped by the words of their headline and summary; each newsroom counts once; figures are read from the reports as published. Nothing here is written by an AI.